Literature DB >> 20233111

The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour.

Thomas Paparrigopoulos1, Panagiotis Ferentinos, Anastasios Kouzoupis, George Koutsis, George N Papadimitriou.   

Abstract

Neuropsychiatric symptoms are common in multiple sclerosis (MS). They include two broad categories of disturbances: abnormalities in cognition, and abnormalities of mood, affect and behaviour. The present review deals with the epidemiology, clinical features, etiology and treatment of disturbances included in the second category, i.e., major depression, fatigue and sleep disorders, bipolar disorder, euphoria, pathological laughing and crying, anxiety, psychosis and personality changes. Major depression is one of the most common neuropsychiatric disorders in MS with an approximate 50% lifetime prevalence rate. Early recognition and management of depression in MS is of major importance because it is a key predictor of morbidity, mortality, quality of life, possibly physical outcome and disease exacerbations, adherence to immunomodulatory treatments and suicide risk in MS patients, as well as of the caregiver's distress and quality of life. The etiopathogenesis of neuropsychiatric disorders in MS has been incompletely investigated. It is postulated that a complex interplay of biological, disease-related, behavioural and psychosocial factors contribute to the pathophysiology of most of them. Management of neuropsychiatric symptoms in MS is often effective, although commonly based on evidence provided by case studies and uncontrolled trials. A comprehensive biopsychosocial neuropsychiatric approach is essential for the optimal care of patients with MS.

Entities:  

Mesh:

Year:  2010        PMID: 20233111     DOI: 10.3109/09540261003589323

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN: 0954-0261


  38 in total

1.  Treatment of mood disorders in multiple sclerosis.

Authors:  Luis Pintor Pérez; Roberto Sánchez González; Eva Baillés Lázaro
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

2.  Effects of the anti-multiple sclerosis immunomodulator laquinimod on anxiety and depression in rodent behavioral models.

Authors:  Irit Gil-Ad; Ben H Amit; Liat Hayardeni; Igor Tarasenko; Michal Taler; Ravit Uzan Gueta; Abraham Weizman
Journal:  J Mol Neurosci       Date:  2014-07-27       Impact factor: 3.444

3.  Sleep disorders in patients with multiple sclerosis in China.

Authors:  Shengli Ma; Xue Rui; Peiyi Qi; Gangqiong Liu; Jing Yang
Journal:  Sleep Breath       Date:  2016-10-11       Impact factor: 2.816

Review 4.  [Coexistent depressive and anxiety disorders in epilepsy and multiple sclerosis: a challenge to neuropsychiatric practice].

Authors:  Hans-Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2014-05-20

5.  Polypharmacy in Multiple Sclerosis: Current Knowledge and Future Directions.

Authors:  Joanie Thelen; Valeriy Zvonarev; Sarah Lam; Crystal Burkhardt; Sharon Lynch; Jared Bruce
Journal:  Mo Med       Date:  2021 May-Jun

Review 6.  Wellness and the Role of Comorbidities in Multiple Sclerosis.

Authors:  Brandon P Moss; Mary R Rensel; Carrie M Hersh
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

7.  The Effect of Type D Personality on Quality of Life in Patients with Multiple Sclerosis.

Authors:  Seden Demirci; Kadir Demirci; Serpil Demirci
Journal:  Noro Psikiyatr Ars       Date:  2016-09-01       Impact factor: 1.339

Review 8.  Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression.

Authors:  Charles L Raison; Christopher A Lowry; Graham A W Rook
Journal:  Arch Gen Psychiatry       Date:  2010-12

9.  Cognitive phenotypes in multiple sclerosis.

Authors:  Victoria M Leavitt; Gabriella Tosto; Claire S Riley
Journal:  J Neurol       Date:  2018-01-22       Impact factor: 4.849

Review 10.  Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series.

Authors:  Stacey Murray; Andrew Woo
Journal:  Ther Adv Neurol Disord       Date:  2015-12-07       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.